FY results are ahead of our forecasts, mainly as a result of higher than expected NCE collaborative revenue, with Tuzistra™ XR prescriptions broadly in line. Following Complete Response Letters from the FDA for follow-on cough cold programmes CCP-07 and (post period-end) CCP-08, the share trades near all-time lows. Vernalis is currently working closely with Tris Pharma to resubmit the NDAs as soon as possible. We reiterate Hold.
12 Sep 2017
N+1 Singer - Vernalis - Solid FY results driven by NCE collaborations; Tuzistra broadly in line
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Vernalis - Solid FY results driven by NCE collaborations; Tuzistra broadly in line
FY results are ahead of our forecasts, mainly as a result of higher than expected NCE collaborative revenue, with Tuzistra™ XR prescriptions broadly in line. Following Complete Response Letters from the FDA for follow-on cough cold programmes CCP-07 and (post period-end) CCP-08, the share trades near all-time lows. Vernalis is currently working closely with Tris Pharma to resubmit the NDAs as soon as possible. We reiterate Hold.